<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Real-Time Oncology Review; Guidance for Industry; Availability</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <style>
        body { font-family: Arial, sans-serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { color: #333; }
        .metadata { color: #666; font-size: 0.9em; }
        .summary { margin-top: 20px; line-height: 1.5; }
        .source { margin-top: 20px; }
    </style>
</head>
<body>
    <h1>Real-Time Oncology Review; Guidance for Industry; Availability</h1>
    <div class="metadata">Published: 2026-02-05 13:28:03</div>
    <div class="summary">The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Real-Time Oncology Review (RTOR)." The purpose of this guidance is to provide recommendations to applicants on the process for submission of selected new drug applications (NDAs) and biologics license applications (BLAs) with oncology indications for review under RTOR. This guidance finalizes the draft guidance of the same title issued on July 22, 2022.</div>
    <div class="source">Source: <a href="https://www.federalregister.gov/documents/2023/11/08/2023-24712/real-time-oncology-review-guidance-for-industry-availability" target="_blank" rel="noopener noreferrer">https://www.federalregister.gov/documents/2023/11/08/2023-24712/real-time-oncology-review-guidance-for-industry-availability</a></div>
</body>
</html>
